Cash (USD)

Prepaid expenses and other current assets (USD)

Total Current Assets (USD)

Equipment, net (USD)

In-process research and development (USD)

Vendor deposit (USD)

Deferred offering costs (USD)

Operating lease right-of-use asset (USD)

Total Assets (USD)

Accounts payable (USD)

Accrued expenses and other current liabilities (USD)

Operating lease liability (USD)

Total Current Liabilities (USD)

Deferred tax liability (USD)

Total Liabilities (USD)

Preferred stock (USD)

Common stock (USD)

Additional paid-in-capital (USD)

Accumulated deficit (USD)

Treasury stock, at cost (USD)

Total Stockholders’ Equity (USD)

Total Liabilities and Stockholders’ Equity (USD)

679863d3a4db3c638a42885deb31f0a6baa6fb0f82551028da91934f1b744f9c

Research and development (USD)

General and administrative (USD)

Impairment of in-process research and development (USD)

Impairment of goodwill (USD)

Total Operating Expenses (USD)

Loss From Operations (USD)

Interest (income) expense (USD)

Change in fair value of equity payable (USD)

Pre-Tax Net Loss (USD)

Income tax (provision) benefit (USD)

Net Loss (USD)

Deemed dividend to preferred stockholders (USD)

Net Loss Attributable to Common Stockholders (USD)

Net Loss Per Share - Basic and Diluted (USD)

Weighted Average Number of Common Shares Outstanding - Basic and Diluted (Shares)

01fa32d55f0cc0aadc919408442899baad1e740c1ce4599e004648ceffdc880f

Net loss (USD)

Stock-based compensation (USD)

Issuance of common stock pursuant to vendor agreements (USD)

Shares issued as consideration for extension of lock-up period (USD)

Amortization of debt discount (USD)

Change in fair value of derivative liability (USD)

Depreciation of fixed assets (USD)

Non-cash rent expense (USD)

Deferred tax benefit (USD)

Net Cash Used In Operating Activities (USD)

Proceeds from issuance of common stock in public offering (USD)

Registration and issuance costs associated with common stock issuance (Financing) (USD)

Redemption of Series A Preferred Stock (USD)

Proceeds from issuance of preferred stock in private placement (USD)

Purchase of treasury stock (USD)

Exercise of pre-funded warrants (USD)

Warrant inducement offer - exercise proceeds (USD)

Registration and issuance costs associated with preferred stock issuance (Financing) (USD)

Exercise of warrants (USD)

Net Cash Provided By (Used In) Financing Activities (USD)

Net (Decrease) Increase in Cash (USD)

Conversion of convertible notes payable and accrued interest into preferred stock (USD)

Conversion of convertible notes payable and accrued interest into common stock (USD)

Reclassification of formerly redeemable common stock (USD)

Warrant modification - incremental value (USD)

Warrant inducement offer - incremental value (Supplemental) (USD)

Security deposit (USD)

Vendor deposits (USD)

Cash - Beginning of Period (USD)

Cash - End of Period (USD)

Recognition of ROU asset and lease liability upon adoption of ASC 842 (USD)

Accounts payable for deferred offering costs (USD)

3a29801deb2584629e2ae80b1411a74a4e67e9788a7eedda36caf7ac616ee75d

ZyVersa Therapeutics (ZVSA)

Financials